Frost, Hannah http://orcid.org/0000-0002-4398-0382
Graham, Donna M.
Carter, Louise
O’Regan, Paul
Landers, Dónal
Freitas, André
Funding for this research was provided by:
AstraZeneca (119106, 119106, 119106, 119106, 119106, 119106)
Article History
Received: 5 January 2022
Revised: 22 June 2022
Accepted: 13 July 2022
First Online: 8 August 2022
Competing interests
: This work is funded in part through a grant awarded by AstraZeneca. Hannah Frost, Donna M. Graham and Louise Carter are all authors of a paper used in this review. Dónal Landers is a director of DeLondra Oncology Ltd., which provides Pharmaceutical Medicine consultancy to Astrazeneca Ltd and Athenex plc.
: As this work is based on searches of the published literature, no additional ethics approval was required.
: Not applicable.